Ebastine in chronic urticaria: A double-blind placebo-controlled study
Ebastine in chronic urticaria: A double-blind placebo-controlled study
复制标题
依巴斯汀治疗慢性荨麻疹：一项双盲安慰剂对照研究
DOI：
10.3109/09546639109086774
复制
发表时间：
1991
期刊：
影响因子：
--
通讯作者：
X. Luria
中科院分区：
文献类型：
--
作者：
J. Peyri;J. Vida;J. Marrón;E. Fonseca;E. Suárez;A. Ledo;J. Zayas;X. Luria
在204例慢性荨麻疹患者中，以双盲对照研究了依巴斯汀10 mg每日一次与安慰剂的作用。依巴斯汀治疗7天和14天后，研究者和患者评估的症状严重程度显著降低。该药物在大多数患者中耐受性良好，副作用的总体发生率与安慰剂无显著差异。它的结论是依巴斯汀代表了一种有效的和耐受性良好的替代其他非镇静抗组胺药治疗慢性荨麻疹。
The effect of ebastine 10 mg once daily was studied in a double-blind comparison with placebo in 204 patients with chronic urticaria. Symptom severity, as assessed by both investigator and patient, was significantly reduced by ebastine after 7 and 14 days of treatment. The drug was well tolerated in the majority of patients, with the overall incidence of side-effects not significantly different to that of placebo. It is concluded that ebastine represents an effective and well-tolerated alternative to other non-sedating antihis-tamines in the treatment of chronic urticaria.